Jupiter Life Line Hospitals Ltd. (JLHL) AI Stock Analysis

• Market Cap: ₹83.93B
• Dividend Yield: 0.14%
• Average Volume (3M): 947.00
• Price to Earnings (P/E): 53.7
• Beta (1Y): 0.10
• Revenue Growth: 18.40%
• EPS Growth: 7.30%
• Country: IN
• Employees: 4,586
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 7.00
• Shares Outstanding: 65,566,025
• 10 Day Avg. Volume: 721
• 30 Day Avg. Volume: 947
• PEG Ratio: 14.64
• Price to Book (P/B): 7.55
• Price to Sales (P/S): 8.12
• P/FCF Ratio: -151.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 29
• Revenue Forecast (FY): ₹14.77B

• Rating: 67 Neutral
• Price Target: ₹1,391.00 ▼(-9.83% Downside)
• Action: N/A Date: 10/02/25
• Date: Action: N/A 10/02/25

Jupiter Life Line Hospitals Ltd. has a strong financial foundation with consistent revenue and profit growth, which is the most significant factor. Technical analysis indicates a stable upward trend, but the high P/E ratio suggests overvaluation, impacting the overall score.

Positive Factors

Consistent revenue and profit growth

Sustained revenue and profit growth indicates steady demand for tertiary/quaternary services and effective pricing and mix. Over 2–6 months this supports reinvestment in facilities and specialties, strengthens bargaining with payors, and underpins long-term margin resilience.

Healthy balance sheet with manageable leverage

A balanced debt profile and robust ROE provide financial flexibility to fund capacity expansion, absorb demand shocks, and negotiate favorable financing. This structural strength reduces solvency risk and supports strategic investments and partnerships over the medium term.

Improving margins and operational efficiency

Rising gross and net margins plus strong EBIT/EBITDA reflect operational discipline and better cost absorption across hospitals. Structural margin improvement signals durable competitive advantages in service mix, higher-value procedures, and scale-driven cost efficiencies over coming quarters.

Negative Factors

Negative free cash flow growth

Declining free cash flow growth constrains the company’s ability to self-fund capex, network expansion, and working capital needs. Persistent FCF weakness can increase reliance on external financing or delay strategic projects, affecting medium-term capacity and margin maintenance.

EPS contraction

Negative EPS growth suggests earnings per share lag recent performance, possibly from margin pressure, one-offs, or dilution. Over several months continued EPS contraction can erode investor returns and indicates potential operational or capital-structure issues needing corrective actions.

Low dividend yield and shareholder cash return

Minimal dividend yield implies limited direct cash returns to shareholders. Combined with negative free cash flow growth, this raises concerns about capital allocation priorities and the company’s ability to deliver meaningful cash distributions or buybacks in the medium term.

Jupiter Life Line Hospitals Ltd. Business Overview & Revenue Model

Company Description

Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company provides treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, ENT, endocrinology and diabetes, gastroenterology, general surgery and minimal access surgery, HPB and surgical gastroenterology, hematology and BMT, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, and urology. It also operates breast care center, chest medicine, and pain clinic departments, as well as hotel under the Fortune Park Lake City Hotel name in Thane. The company was incorporated in 2002 and is based in Mumbai, India.

How the Company Makes Money

JLHL primarily makes money by providing hospital and clinical healthcare services to patients. Key revenue streams typically include (1) inpatient services such as room/bed charges, ICU/critical care, operating theatre and procedure charges, nursing and clinical care fees; (2) outpatient services including physician consultations and follow-up visits; (3) diagnostic services such as imaging and pathology/lab tests provided to inpatients and outpatients; (4) pharmacy and consumables, including medicines, implants, and medical supplies used during treatment episodes; and (5) specialized procedures and surgeries across multiple specialties, where revenue is driven by case volumes, complexity, and utilization of hospital infrastructure. Payments generally come from a mix of cash-paying patients and third-party payors (e.g., insurers and corporate/TPA arrangements) through reimbursement or cashless billing. Material details on specific partner organizations, payer mix, segment-level revenue split, or facility-wise revenue contribution are null.

Jupiter Life Line Hospitals Ltd. Financial Statement Overview

Summary

Jupiter Life Line Hospitals Ltd. demonstrates strong financial health with consistent revenue and profit growth. The balance sheet is stable with manageable leverage, but cash flow management requires attention due to negative free cash flow growth.

Income Statement

Jupiter Life Line Hospitals Ltd. has shown consistent revenue growth over the years, with a notable increase in gross profit margins, indicating efficient cost management. The net profit margin has improved, reflecting enhanced profitability. EBIT and EBITDA margins are strong, showcasing operational efficiency.

Balance Sheet

The company has a healthy debt-to-equity ratio, indicating a balanced approach to leveraging. The return on equity is robust, suggesting effective use of shareholder funds. The equity ratio is stable, reflecting a solid financial foundation.

Cash Flow

While operating cash flow is strong, the negative free cash flow growth and ratio to net income indicate potential challenges in cash management. The operating cash flow to net income ratio is healthy, but improvements in free cash flow are needed.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	13.93B	12.62B	10.70B	8.93B	7.33B	4.86B
Gross Profit	11.31B	10.31B	8.55B	7.11B	4.07B	2.41B
EBITDA	3.63B	3.25B	2.61B	2.06B	1.50B	637.55M
Net Income	1.98B	1.93B	1.77B	729.05M	511.28M	-22.97M
Balance Sheet
Total Assets	20.23B	19.05B	12.81B	9.86B	9.09B	7.89B
Cash, Cash Equivalents and Short-Term Investments	5.64B	6.03B	3.18B	1.36B	1.06B	266.46M
Total Debt	4.03B	3.93B	623.41M	4.69B	4.95B	4.26B
Total Liabilities	5.72B	5.49B	1.13B	6.22B	6.20B	5.42B
Stockholders Equity	14.51B	13.56B	11.69B	3.66B	2.94B	2.39B
Cash Flow
Free Cash Flow	-403.95M	-674.22M	292.26M	399.24M	452.40M	-1.18B
Operating Cash Flow	1.30B	2.53B	1.15B	1.17B	1.37B	1.23B
Investing Cash Flow	-1.73B	-2.09B	-758.89M	-1.04B	-852.46M	-2.96B
Financing Cash Flow	-231.75M	3.01B	1.28B	175.00M	322.02M	1.84B

Jupiter Life Line Hospitals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1542.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JLHL, the sentiment is Positive. The current price of 1542.6 is above the 20-day moving average (MA) of 1262.79, above the 50-day MA of 1287.55, and above the 200-day MA of 1422.45, indicating a neutral trend. The MACD of -5.04 indicates Negative momentum. The RSI at 51.91 is Neutral, neither overbought nor oversold. The STOCH value of 49.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JLHL.

Jupiter Life Line Hospitals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	71 Outperform	₹345.38B	75.82	―	0.24%	14.72%	8.37%
JLHL	67 Neutral	₹83.93B	53.67	―	0.14%	18.40%	7.30%
KIMS	65 Neutral	₹269.25B	114.01	―	―	25.74%	1.41%
MEDANTA	65 Neutral	₹281.36B	83.79	―	0.04%	15.78%	15.01%
ASTERDM	62 Neutral	₹342.87B	151.95	―	0.84%	-36.14%	-93.99%
FORTIS	61 Neutral	₹638.43B	86.12	―	0.11%	15.33%	54.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Jupiter Life Line Hospitals Ltd. Corporate Events

Jupiter Life Line Hospitals Publishes Q3 and Nine-Month FY2025 Unaudited Results

Jupiter Life Line Hospitals Ltd. has published its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, following approval by its board on January 30, 2026. The company reported growth in operational income, with consolidated revenue from operations reaching ₹3,744.96 million for the quarter and ₹11,451.68 million for the nine-month period, alongside steady profitability reflected in net profit and earnings per share metrics. The results were released via newspaper advertisements in Financial Express and the Marathi daily Pudhari and are also available on the company’s website, underscoring its compliance with SEBI’s disclosure norms and providing investors and other stakeholders with updated visibility into its financial performance for the current fiscal year.